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NOD2 variants have been identified to be a susceptibility factor for Crohn's disease. TheNOD2 protein
is an intracellular sensor of the bacterial wall product muramyl dipeptide (MDP) and activates the
transcription factor NF-kappaB upon MDP-binding. NOD2 variants are associated with reduced NF-
kappaB activation and reduced production of epithelial derived antibacterial peptides such as
defensins. A reduced expression of defensins is described and found in patients with Crohn's disease
and ulcerative colitis especially when NOD2 variants are present. Furthermore recent evidence from
mouse models suggests that the ability of intestinal epithelial cells to activate NF-kappaB upon
bacterial stimulation protects from mucosal inflammation.
Taken together these data indicate that NOD2 mediated NF-kappaB activation, subsequent
induction of anti-microbial peptides such as defensins and induction of cytokine expression are
essential for the function of the intestinal barrier and for theprevention of bacterial translocation. The
data indicate why a defect in the induction of this acute defense response is associated with chronic
inflammation. Invading bacteria that cannot be readily detected and eliminated may start a backup
mechanism of inflammation finally resulting in chronic inflammatory reaction followed by further
impairment of the mucosal barrier.
© 2007 European Crohn’s and Colitis Organisation. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.KEYWORDS
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Genetic factors have been postulated to be involved in the
pathogenesis of IBD. The search for “risk genes” had an initial
success in 1996 when the first susceptibility locus for Crohn's
disease (CD) was identified in the pericentromeric region of
chromosome 16 and later named “IBD1”.1 In 2001 a CAspase
Recruitment Domain containing protein NOD2/CARD15 was
found to be mutated in 20–30% of CD patients making it the
proof of principle of the “genetic concept” of IBD pathophy-
siology.2–4 Multiple mutations in the NOD2/CARD15 gene
have been identified, three of which have been shown to be
independently associated with CD (arg702trp, gly908arg, and
leu1007fsinsC).5–7 NOD2/CARD15 mutations are associated
with ileal disease,8–12 earlier onset of disease13,14 and
stricturing disease.14–16
2. NOD2/CARD15 expression in the intestinal
mucosa
NOD2/CARD15 is mainly expressed in the cytoplasm of
macrophages and other mononuclear cells (antigen presenting
cells) in the colon.17–19 In the ileum strong additionally
expression is found in Paneth cells.18,20–22 But also colonic
epithelial cells have been shown to express this protein,Figure 1 Pattern recognition receptors (PRRs) in intestinal epithel
resulting in IKK activation, IκB degradation and finally in NF-κB transl
Nod2 their CARD domains interacts with the CARD domain of RICK foll
two kinase proteins IKKα and IKKβ and the regulatory protein NEMOhowever, to lower mRNA levels as compared to Paneth cells or
intestinal macrophages.17,18,21,23–27 Increased NOD2/CARD15
is found in intestinal epithelial cells (IECs) and macrophages in
CD lesions.21 NOD2/CARD15 mRNA and protein expression are
induced by pro-inflammatory factors such as tumour necrosis
factor alpha (TNFalpha).26,27 Another regulator of NOD2/
CARD15 gene expression present in increased amounts in CD
mucosa is interferon gamma (IFNγ).26 This indicates that
inflammation may induce increased levels of NOD2/CARD15
protein in IECs as well as intestinal macrophages (IMACs). In
normal mucosa IMACs are in a functional tolerogenic and
anergic state.28,29 They cannot be stimulated by bacterial
products such as LPS as they show absent or decreased
expression of a number of relevant receptors.28 However, in CD
patients they display these receptors allowing activation28 and
secrete large amounts of pro-inflammatory cytokines. This
could be followed by induction of NOD2/CARD15 expression in
IECs and — in an autocrine pathway — IMACs.
3. NOD2/CARD15 is a pattern recognition
receptor (PRR)
NOD2/CARD15 is a member of a superfamily of genes, the NBS-
LRR proteins (nucleotide-binding site and leucine-rich repeat),
which are involved in intracellular recognition of microbes andial cells such as TLRs and NODs utilize distinct signalling cascades
ocation and activation. After binding of MDP to the LRR domain of
owed by IKK-complex activation. The IKK complex consists of the
.
55The effects of NOD2/CARD15 mutations on the function of the intestinal barriertheir products and include Apaf-1 and NOD1/CARD4.30 NBS-LRR
proteins are characterized by a C-terminal leucine-rich repeat
(LRR) domain able to sense a microbial motif, an intermediary
nucleotide binding site (NBS) essential for the oligomerization
and signal transduction and a caspase-activating and recruit-
ment domain (CARD)30 (Fig. 1). In contrast to NOD1, NOD2 has
two CARD domains, which are also found in most caspases
(Fig. 1). They form a three-dimensional structure that is very
similar to the death domains of apoptotis related proteins. The
CARD domains mediate protein–protein interaction through
homophilic binding (Fig. 1).
NBS-LRR proteins play an important role in the innate
immune system. The family also includes such proteins as Nalp
molecules and some transcriptional regulator such as IPAF. Most
of the mentioned proteins are involved in inflammatory
responses and a number of auto-immune diseases are related
to mutations in these family members.31 There is a second class
of “detectionmolecules” for bacterial and viral products, the so
called toll like receptors (TLRs) (Fig. 1). Both classes ofmicrobial
product sensors are classifiedas“pattern recognition receptors”
(PRRs). After being activated by the presence of microbial
ligands they usually initiate a defence response. The microbial
ligands of PRRs have been termed “pathogen-associated
molecular patterns” (PAMPs), however, not all molecules
detected are always pathogenic; for example bacterial or viral
DNAmotifs bound by TLR-9may induce amelioration of colitis as
well as aggravation depending on the circumstances.32–34
The microbial patterns recognised by PRRs are evolu-
tionary highly conserved. Both classes of PRRs are involved in
detecting potentially harmful microbes through PAMP recog-
nition followed by the initiation of a defence reaction and
sometimes but not always typical inflammation with activa-
tion of the adaptive immune system. Defence reactions
beside activation of the adaptive immune system may be the
secretion of locally acting antibacterial molecules such as
oxygen radicals35 or defensins (see below).
In the far most situations the intestinal mucosa will not
be confronted with just one specific single PAMP but with an
entire microbe or a number of different microbes exposing
the mucosa to a multitude of different PAMPs at the same
time. Therefore, it is likely that we will have to deal with
typical “PAMP-patterns” to learn more about defence
reactions and barrier functions of the intestinal mucosa in
the future. NOD2 (similar to NOD1) recognises peptidoglycan
(PGN), although both detect different motifs within this
structure. PGN is the major constituent of the cell wall of
Gram-positive bacteria. In Gram-negative bacteria it is
found in a thin layer in the space between the outer and
cytoplasmic membranes. The NOD2 protein has been found
to bind and recognize muramyl dipeptide (the minimal motif
in all PGNs) mediating consecutive NF-κB activation (see
below).30,36–38
4. NOD2/CARD15 induced signal transduction
After ligand binding the NOD2 protein associates with a
serine/threonine kinase called RIP2 (also known and RICK or
CARDIAK) through a homophilic CARD–CARD interaction
(Fig. 1).39,40 This followed by the activation of RIP2 by a
mechanism called “induced proximity”41 involving oligomer-
ization and further activation. Activated RIP2 then interacts
with the regulatory subunit of the IKK complex, IKKγ or NEMO(Fig. 1).41 Subsequent phosphorylation of IκBα, degradation
of IκBα and release and nuclear translocation of NF–κB
occur.19,42,43
NF–κB is known to induce the expression of pro-inflamma-
tory mediators such as TNF or IL-1 as well as other cytokines,
chemokines, adhesion molecules or many more. NF-κB is
activated after binding of ligands to various PRRs such as NOD
proteins and Toll like receptors (TLRs).
Variants of the NOD2/CARD15 gene as found in CD are
associated with an impaired activation of NF-κB in vitro in
transfection experiments.38 The frameshift variant,
Leu1007fsinsC, truncates the LRR domain and is associated
with a markedly reduced NF-κB activation.38 In comparison,
the Arg702Trp and Gly908Arg variants respond more to
stimulation with bacterial wall products than the Leu1007f-
sinsC variant, however, the ability to activate NF-κB is still
significantly reduced.
These data indicate that a reduced ability to activate NF-
κB in response to intestinal bacteria may trigger CD.17,44–46
This is in contrast to the paradigm of a primarily hyper-
responsive mucosal immune system being the cause of CD. As
NF-κB is activated by pattern recognition receptors such as
TLRs or NOD2 and NOD2 variants lead to defects in innate
immune and epithelial barrier functions it was speculated
that inhibition of NF-κB might also be associated with
impaired innate immunity. Indeed evidence for a protective
role of NF-κB has been found. Recently it was demonstrated
that intestinal epithelial cell-intrinsic IKKβ-dependent gene
expression is a critical regulator of responses of dendritic
cells and T cells in the intestinal mucosa.47,48 Mice with an
epithelial-specific deletion of IKKβ showed a reduced
expression of the cytokine lymphopoietin in the intestinal
mucosa and, after infection with the parasite Trichuris, failed
to develop a pathogen-specific Th2 response associated with
persisting infection. In addition these animals showed
increased production of interleukin-12/23p40 and TNF lead-
ing to severe intestinal inflammation.48 Further evidence was
found for an important role of NF-κB for intestinal epithelial
integrity and the interaction between the mucosal immune
system and gut microflora. In a mouse model of epithelial-
cell-specific inhibition of NF-κB through a epithelial-specific
deletion of NEMO severe chronic intestinal inflammation
occurred associated with increased apoptosis of colonic
epithelial cells, impaired expression of antimicrobial peptides
and translocation of bacteria into the mucosa.49 Deficiency of
MyD88 is associated with a lack of TLR induced signalling (see
Fig. 1). MyD88 deficiency prevented the development of
intestinal inflammation indicating that TLR-ligation is essen-
tial for disease pathogenesis in this mouse model.49
These findings demonstrate that a complete lack of PRR
(or PAMP respectively) induced NF-κB activation in intestinal
epithelial cells is associated with mucosal inflammation. NF-
κB activation may be essential for epithelial cell protection
and innate defence mechanisms especially in a state of acute
challenge such as bacterial translocation. In this situation an
acute inflammatory response might be necessary to elim-
inate the invading microbiotics.
Besides NF-κB induction, NOD2 has been shown to be
involved in the induction of apoptosis. NOD2 may interact with
the CARD domain of caspase 9 and potentiate an apoptotic
response induced by other triggers. Evidence for an involve-
ment of NOD2/CARD15 into epithelial cell apoptosis has been
56 G. Roglerderived from overexpression experiments thus not directly
allowing conclusion for the in vivo situation. InCDpatients a loss
of the potentiation of apoptosis by the presence of NODs/
CARD15 variants could be followed by an altered ability to
undergo regular apoptosis and anoikis which could favour the
development of necrosis. This might result in the generation of
‘danger signals’ promoting the induction of inflammation and
an impairment of the epithelial barrier. Necrosis of epithelial
cells could also be relevant in the pathogenesis of ulcers.
5. Anti-microbial peptides and the mucosal
barrier function
The intestine is a reservoir of bacteria and of bacterial products
(endotoxins, exotoxins, and cell wall fragments) that may
escape from the intestinal lumen to the mesenteric lymph
nodes and the bloodstream. The intestinal mucosa is the major
barrier against those bacteria and toxins, protecting the body
from the potentially harmful pathogens.50–52 Under physiolo-
gical conditions the integrity of the intestinal mucosal barrier is
maintained by a combination of mechanical, biochemical, and
immunological mechanisms. The mechanical barrier is formed
primarily by the epithelial cells and by their intercellular
junctions.53–55 They also are part of innate immune mechan-
isms. Alterations in one these components of the intestinal
barrier have been reported to be responsible for bacterial and
endotoxin translocation. As discussed the cells of the intestinal
mucosa express a number of PRRs which detect microbial
components extra- or intra-cellularly.27,56
A component of the biochemical defense mechanisms of
the intestinal barrier is the luminal secretion of molecules,
such as defensins and cathelicidins that directly destroyFigure 2 In the cytoplasm the NF-κB complex is associated
phosphorylates IκB at serine32 and serine36. This is followed by
proteasomal degradation of IκB and a translocation of the activated N
κB dimer interacts with cofactors, corepressors and regulatory NF-κB
induction of gene transcription of defense genes such as defensins omicroorganisms.57,37,36 In mammals, defensins are the
predominant anti-microbial polypeptides.57 Defensins have
the capability to kill and/or inactivate a large spectrum of
bacteria, fungi, and viruses. Six β-defensins (hBD-1 to hBD-6)
have been identified in humans.58 hBD-1 is constitutively
expressed, whereas hBD-2 and hBD-3 can be induced by
microbial products and cytokines, such as IL-1 and TNF.58–60
Thus, β-defensins play an important crucial role for the
barrier function of the intestinal mucosa especially as they
are inducible upon challenge.61
6. NOD2 activation and production of
antimicrobial peptides
MDP–NOD2/CARD15 interaction is followed by activation of
the innate immune system reflected by an induction of α- and
β-defensins secretion as a first line of defense at the mucosal
barrier in response to a bacterial attack. NOD2 protein
activation furthermore increases the production of pro-
inflammatory cytokines such as TNFα, IL-1β or IL-8 (Fig. 2),
which also reflects an early defense mechanism.23,36,62,63
In epithelial cells MDP binding to NOD2 is specifically
followed by an induction of the expression of the inducible
antimicrobial peptide hBD-2.63 The hBD-2 promoter contains
putative binding sites for NF-κB providing an explanation
how NOD2 activation may induce hBD-2 transcription
(Fig. 2).63 Mutation of the two proximal NF-κB sites in the
hBD-2 promoter region almost completely inhibits the MDP-
induced hBD-2 promoter activation in NOD2-overexpressing
cells.63
Another protein important for intestinal barrier function
which also seems to be modulated in its expression by NOD iswith the inhibitory protein IκB. The activated IKK complex
release of IκB from the NF-κB complex. Consecutive a rapid
F-κB into the nucleus take place. In the nucleus the activated NF-
elements in promoters. In epithelial cells this is followed by an
r DMBT-1.
Figure 3 NOD2 mediates NF-κB activation in epithelial cells which is followed by an induction of anti-microbial peptides such as
defensins and induction of cytokine expression. This mechanism is essential for the function of the intestinal barrier and for the
prevention of bacterial translocation. If NOD2 variants are present a defect of this acute defense response occurs followed by a leaky
barrier, bacterial invasion and subsequent chronic inflammation finally further impairing the mucosal barrier.
57The effects of NOD2/CARD15 mutations on the function of the intestinal barrier“deleted in malignant brain tumors 1” (DMBT1).24 DMBT1
belongs to the group of secreted scavenger receptor
cysteine-rich proteins and is considered to be involved in
host defense by pathogen binding. Intestinal epithelial cells
up-regulate DMBT1 expression upon proinflammatory stimuli
(e.g., TNF, LPS).24 DMBT1 inhibits cytoinvasion of Salmonella
enterica and LPS- and muramyl dipeptide-induced NF-κB
activation and cytokine secretion in vitro.24 Following MDP
mediated activation of NOD2, expression is DMBT1 is strongly
up-regulated. Increased expression is found in the inflamed
intestinal mucosa of Crohn's disease patients with wild-type,
but not with mutant NOD2.24 Dysregulated intestinal DMBT1
expression due to mutations in the NOD2/CARD15 gene may
be another mechanism responsible for the dysfunction of the
intestinal barrier in CD.
7. NOD2 variants are associated with reduced
production of defensins
Analyses of CD patients with wild type (wt) NOD2 showed
that the expression of human α-defensin 5 (HD5) is
approximately 50% decreased as compared to controls.64
HD6 levels were similarly reduced. In contrast no significant
changes in most other Paneth cell antibacterial factors were
found, suggesting a specific defect of α-defensin production.In a parallel study, the same group found normal levels of
β-defensins in CD patients whereas there were increased
levels of β-defensins 2 and 3 in ulcerative colitis (UC)
patients.65 Therefore, Wehkamp and colleagues suggested
that in CD there is also a lack of β-defensin induction and
thus a relative deficiency of this defensin again overall
contributing to impaired barrier functions.
One of the first findings indicating a role of NOD2 for
intestinal barrier function was the finding that NOD2 is
involved in the regulation of α-defensin expression. As
mentioned above NOD2 is expressed in Paneth cells and
protects epithelial cells from bacterial infection. Mutations in
NOD2/CARD15 have been demonstrated to affect α-defensin
production in patients with CD. Patients carrying the so called
SNP15 variant (a frameshift mutation at Leu1007) were
identified to exhibit a further decrease in mucosal HD5 levels
than that seen in NOD2 wt CD patients.64
Nevertheless it is not unequivocally proven that the
reduction in defensin production and subsequent deficiency
in antibacterial activity caused by NOD2 variants (or at least
one of the three major NOD2 variants) is a major factor in the
pathogenesis of CD. An impairment of mucosal barrier function
can itself be a cause of gut inflammation. A chimeric mouse
expressing a dominant-negative N-cadherin transgene in the
intestinal epithelium, followed by leaky tight junctions
between cells developed severe mucosal inflammation.66
58 G. RoglerFurther arguments are needed to connect NOD2 variants with
impaired barrier function of the intestinal mucosa.
8. NOD2/CARD15 and barrier function
Intestinal epithelial cells expressing mutated NOD2 are not
able to respond appropriately to an in vitro challenge with
Salmonella.46 The survival of Salmonella typhimurium in
human intestinal Caco-2 cells was shown to be altered by the
expression of NOD2.27 Nod2-deficient mice exhibit lower
expression levels of cryptidins, the murine orthologs of
human β-defensins, and exhibit a higher susceptibility to
infection with Listeria monocytogenes.36 NOD2 mediates
intracellular bactericidal activity possibly via interaction
with GRIM-19, a protein with homology to the NADPH
dehydrogenase complex.67
Increased intestinal permeability has long been described in
patients with CD.68–72 Clinical investigation of large pedigrees
has suggested that the pattern of increased permeability in
families with CD follows an autosomal recessive mode of
inheritance. The increased permeability in CD is associated
with the presence of NOD2 variants.73,74 These findings suggest
that indeed NOD2 variants could be the underlying genetic
defect that causes a defect of intestinal barrier functions
(Fig. 3).
9. Epithelial barrier and graft versus host
disease
Further arguments for the crucial role of NOD2 for intestinal
barrier function besides its role in the pathophysiology of CD
are findings in a completely different group of patients.
Individuals suffering from intestinal graft versus host disease
(GvHD) after allogeneic bone marrow transplantation (SCT)
show histological features similar to CD. GvHD is associated
with increased intestinal permeability and could therefore
also be a problem of a defective intestinal barrier. It is still the
most severe complication following SCT. Experimental models
indicate the primacy of gastrointestinal damage: Conditioning
related damageof the intestinal epithelium results in bacterial
translocation followed by increased cytokine release by
macrophages/monocytes and Tcell activation.75,76
The incidence of severe GvHD (and associated gastro-
intestinal GvHD) rose from 18% in donor/recipient pairs
without any NOD2/CARD15 variants to 37% in pairs with
either donor or recipient mutations with a subsequent
increase of treatment related mortality (TRM) from 33 to
60%.77–79 When donor/recipient pairs both had NOD2/
CARD15 mutations severe GvHD rose from 22 to 55% and
transplantation related mortality from 38% to 100%.77–79
As the stem cell donors also seemed to have a major
impact further conclusion can be drawn for NOD2 functions on
the intestinal barrier: A NOD2 variant mediated altered
pathway of activation of intestinal macrophages or antigen
presenting cells (APCs) might be an additional important
mechanism that could at least explain the strong association
of NOD2/CARD15 variants with GvHD. When the causes of
death in the investigated SCT-patient cohorts were analyzed
GvHD and progressive pulmonary failure resembling adult
respiratory distress syndrome were themajor causes of death
in recipient/donor pairs with NOD2/CARD15 variants.78,79 AsAPCs express NOD2, the altered pathways of APC activation
might not only be relevant for the intestinal barrier but also
involve other organs forming a barrier against the exterior,
such as the lung.
A deficient antibacterial response in both, IEC/Paneth
cells of the recipient's mucosa and donor monocytes might
result in increased bacterial translocation and subsequent
mucosal inflammation. Assuming a comparable pathophy-
siology in GvHD and CD, these data suggest that the primary
pathophysiology in a subgroup of CD patients is an IEC — and
monocyte/macrophage defect in bacterial product recogni-
tion and that alterations in T-cell function may be secondary.
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